Table 2 Baseline demographics and clinical characteristics of the 200182 trial population and the exit interview population
Demographics | Total clinical trial (N = 96) | Total exit interview (N = 67) | 60-minute interview (n = 32) | 15-minute interview (n = 35) |
|---|---|---|---|---|
Age (years), mean (SD) | 65.1 (7.1) | 65.1 (7.2) | 64.6 (8.2) | 65.5 (6.5) |
Female, n (%) | 47 (49.0) | 36 (53.7) | 14 (43.8) | 22 (62.9) |
Race n (%) | Â | Â | Â | Â |
 White/Caucasian/European  African American/African | 91 (94.8) 7 (5.2) | 64 (95.5) 3 (4.5) | 29 (90.6) 3 (9.4) | 35 (100.0) |
Country, n (%) | Â | Â | Â | Â |
 USA  Germany  UK | 51 (53.1) 33 (12.5) 12 (12.5) | 39 (58.2) 19 (28.4) 9 (13.4) | 24 (75.0) 7 (18.8) 2 (6.3) | 15 (42.9) 13 (37.1) 7 (20.0) |
Clinical characteristics | Â | Â | Â | Â |
Baseline predicted FEV1(%), mean (SD) | 48.8 (10.8) | 50.3 (10.7) | 52.3 (11.3) | 48.4 (9.8) |
BMI (kg/m2), mean (SD) | 25.0 (4.2) | 25.2 (4.2) | 24.3 (3.9) | 26.1 (3.9) |
CAT score, mean (SD) | 18.4 (6.5) | 18.6 (6.6) | 18.6 (6.4) | 18.6 (6.9) |
Trial treatment arm, n (%) | Â | Â | Â | Â |
 Treatment  Placebo | 49 (51.0) 47 (49.0) | 35 (52.2) 32 (47.8) | 17 (53.1) 15 (46.9) | 18 (51.4) 17 (48.6) |